Correlation of HER2/neu antibody response to clinical response in a Phase II trial of the ae37+gm-csf her2 peptide vaccine

Documenti analoghi

• Preliminary results of the Phase IIa trial of a folate binding protein (FBP) adjuvant cancer vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence
  di: Greene, Julia, et al.
  Pubblicazione: (2014)
• Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine
  di: Jackson, Doreen, et al.
  Pubblicazione: (2015)
• Vaccine-specific T-cell proliferation in response to a dual peptide cancer vaccine in breast and ovarian cancer patients
  di: Schneble, Erika J, et al.
  Pubblicazione: (2013)
• Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
  di: Brown, Tommy A., et al.
  Pubblicazione: (2020)
• Preliminary results for the phase 1 trial of a folate receptor alpha adjuvant cancer vaccine in ovarian and endometrial cancer patients
  di: Berry, John S, et al.
  Pubblicazione: (2013)